Posted by Michael Wonder on 17 Mar 2021
Sparta Biomedical receives FDA breakthrough device designation for SBM-01 biomimetic implant
17 March 2021 - Sparta Biomedical today announced that its SBM-01 biomimetic implant has been granted a breakthrough device designation from the U.S. FDA.
SBM-01 is intended to replace damaged knee cartilage in patients having single or multiple chondral or osteochondral defects in the knee.
